Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FP9 ME-TRAP
- Development stage
- Phase 2
- Lead developer
- University of Oxford
- Modality
- Viral Vector Vaccines → Recombinant Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
FP9 ME-TRAP is a candidate malaria vaccine developed at the University of Oxford. It uses a highly attenuated fowlpox virus vector (FP9) to deliver the multiple epitope-thrombospondin-related adhesion protein (ME-TRAP) antigen, which is designed to induce strong cellular immune responses, particularly CD8+ T cell responses, against pre-erythrocytic stages of *Plasmodium falciparum*. The ME string includes multiple T and B cell epitopes from several malaria antigens fused to TRAP. FP9 ME-TRAP has been evaluated in prime–boost regimens with other viral vectors such as MVA (modified vaccinia Ankara), aiming to enhance immunogenicity and protection against malaria infection. Clinical trials have shown that while the vaccine can induce immune responses, efficacy in preventing clinical malaria has been limited[2][5][6][7][8].
- Other names
- FP9-ME-TRAP vaccineFP-9-ME-TRAP vaccineFP 9-ME-TRAP vaccine
02
Targets
TRAP (Thrombospondin-related anonymous protein)
Beyond the preview
Go deeper on FP9 ME-TRAP.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FP9 ME-TRAP.